Background
==========

Glucocorticoids are frequently used in the treatment of inflammatory or degenerative diseases, such as rheumatoid arthritis and bronchial asthma \[[@b1-medscimonitbasicres-24-47]\]. However, the use of glucocorticoids can cause osteoporosis \[[@b2-medscimonitbasicres-24-47]\]. Osteoporosis is a very common disease that is characterized by alterations of bone tissue microstructure, decreased bone mineral density (BMD), and increased bone fragility \[[@b3-medscimonitbasicres-24-47]--[@b5-medscimonitbasicres-24-47]\]. Because of the bone changes, osteoporosis is a most important clinical problem, which is expected to become even more prevalent in an increasingly aging population \[[@b6-medscimonitbasicres-24-47]\]. The prevention and treatment of osteoporosis have become an important clinical goal \[[@b7-medscimonitbasicres-24-47],[@b8-medscimonitbasicres-24-47]\]. Current therapy for the prevention and treatment of osteoporosis include bisphosphonates, selective estrogen receptor (ER) modulators, hormone-replacement therapy (HRT), and calcium and vitamin D supplementation \[[@b9-medscimonitbasicres-24-47],[@b10-medscimonitbasicres-24-47]\]. However, due to the side effects of hormone replacement therapy or the susceptibility of some patients to the side effects of bisphosphonates, alternative therapies and drugs continue to be investigated for the treatment of osteoporosis.

A vascular response is required for the healing of bone injuries and fractures, and this response occurs within days of a bone injury when regional blood flow is high, and bone marrow vascular differentiation occurs to aid the repair of fractures \[[@b11-medscimonitbasicres-24-47]\]. Nitric oxide (NO) is a highly reactive molecule, synthesized by the nitric oxide synthase (NOS) enzyme family, from L-arginine \[[@b12-medscimonitbasicres-24-47]--[@b14-medscimonitbasicres-24-47]\]. NO has an effective role in regulating perfusion pressure and blood flow in vascular beds \[[@b8-medscimonitbasicres-24-47],[@b15-medscimonitbasicres-24-47]\]. Cyclic guanosine monophosphate (cGMP) mediates the intracellular effects of NO, and both NO and cGMP are controlled by the activation of protein kinase-G (PKG) \[[@b16-medscimonitbasicres-24-47]\]. NO, has also been shown to have an important regulatory role in osteoblast metabolism, which contributes to the healing of bone damage \[[@b11-medscimonitbasicres-24-47]\].

The ability to maintain the NO intracellular signaling pathway depends on cGMP activity \[[@b17-medscimonitbasicres-24-47]\]. However, phosphodiesterase-5 (PDE-5) selectively hydrolyzes cGMP \[[@b18-medscimonitbasicres-24-47]\]. For this reason, it is possible that PDE-5 inhibitors, including avanafil \[[@b19-medscimonitbasicres-24-47]\], zaprinast \[[@b20-medscimonitbasicres-24-47]\], sildenafil \[[@b21-medscimonitbasicres-24-47]\], vardenafil \[[@b22-medscimonitbasicres-24-47]\], tadalafil \[[@b23-medscimonitbasicres-24-47]\] and udenafil \[[@b24-medscimonitbasicres-24-47]\] may be effective in converting osteoclasts to osteoblasts, increasing the maturation of osteoblasts and increasing bone calcification, and increasing angiogenesis in the bone tissue via preservation of increased cGMP levels \[[@b25-medscimonitbasicres-24-47]\]. Based on the findings from previously published studies, the PDE-5 inhibitors, avanafil \[[@b19-medscimonitbasicres-24-47]\] and zaprinast \[[@b20-medscimonitbasicres-24-47]\] may have a positive effect on bone calcification \[[@b26-medscimonitbasicres-24-47]\]. We have previously shown that PDE-5 inhibition had a positive effect on bone healing in rats with bone damage \[[@b8-medscimonitbasicres-24-47],[@b27-medscimonitbasicres-24-47]\].

Currently, following the review of the previously published literature, there have been no studies on bone mineralization, mechanisms of bone remodeling, and oxidative stress and the use of the PDE-5 inhibitors, avanafil and zaprinast in humans or experimental animals with osteoporosis. In this study, the aim was to examine the effects of the PDE-5 inhibitors, avanafil and zaprinast on endothelial nitric oxide synthase (eNOS), NO, cGMP, PKG, pyridinoline (PD) and deoxypyridinoline (DPD) as markers of bone damage and remodeling in samples of rat urine, and to examine the bone formation markers, C-terminal telopeptide of type I collagen (CTX-1) and procollagen type I carboxy-terminal extension peptide (PICP) in plasma and bone tissue from rats with glucocorticoid-induced osteoporosis (GIOP).

NO is known to cause oxidative stress by leading to the formation of reactive oxygen species (ROS) such as the peroxynitrite ion (ONOO^−^), as well as having beneficial effects on recovery from bone fracture \[[@b28-medscimonitbasicres-24-47]--[@b30-medscimonitbasicres-24-47]\]. To determine whether the PDE-5 inhibitors, avanafil and zaprinast maintain the activity of the NO metabolic pathway, it was assumed that, for this study, it was important to measure how NO levels and oxidative stress in rats with GIOP were affected, a view which is supported by several previous studies on the positive relationship between osteoporosis and oxidative stress \[[@b31-medscimonitbasicres-24-47]--[@b36-medscimonitbasicres-24-47]\]. Therefore, the effect of oxidative damage due to activation of the NO signaling pathway was also investigated, by measuring the lipid peroxidation product malondialdehyde (MDA), the indicator of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine (8-OHdG), and indicators of mitochondrial damage, including the ratio of ubiquinone-10 (CoQ10) to ubiquinol CoQ10 (CoQ10H), in rats with GIOP.

Material and Methods
====================

Chemicals and reagents
----------------------

All chemicals, reagents, and drugs were commercially purchased and were of analytical grade. The phosphodiesterase-5 (PDE-5) inhibitor, zaprinast, thiobarbituric acid, 1,1,3,3-tetraethoxypropane, ubiquinone-10 (CoQ10), 8-hydroxy-2′-deoxyguanosine (8-OHdG), deoxyguanosine (dG), 10% formalin and phosphate buffered saline (PBS) were purchased from Sigma (Catalog numbers: Z0878, T5500, T9889, C9538, H5653, 854999, HT501128, P4417, respectively) (Sigma Aldrich, USA). Osteosoft solution (HC 313331) was purchased from Merck (Merck, Germany) and the PDE-5 inhibitor, avanafil (CID: 330784-47-9) was purchased from PubChem.

Experimental design and development of the rat model of glucocorticoid-induced osteoporosis (GIOP)
--------------------------------------------------------------------------------------------------

For this study, approval was obtained from the Ethics Committee of the Yuzuncu Yıl University Experimental Animals Local Ethics Committee Presidency (REC: 28.11.2013, 2013/13). Twenty-four 8-month-old male rats in four groups were given a single daily treatment during a 30-day period: an (untreated) control group (n=6): a dexamethasone-treated group (120 μ/kg) (n=6); a group treated with dexamethasone (120 μ/kg) and zaprinast (10 mg/kg) (n=6): and a group treated with dexamethasone (120 μ/kg) and avanafil (10 mg/kg) (n=6). During the study, the rats in all groups were fed with standard pellet feed and water with 12-hour light and dark conditions.

The rat model of glucocorticoid-induced osteoporosis (GIOP) was developed by using dexamethasone, derived from synthetic glucocorticoids, according to the method used by Mohd Ramli et al. \[[@b37-medscimonitbasicres-24-47]\]. For effective doses of dexamethasone and the phosphodiesterase-5 (PDE-5) inhibitors, zaprinast and avanafil, the effective dose levels were determined from previous studies and were administrated at daily doses of 10 mg/kg for PDE-5 inhibitors, and 120 μg/kg for dexamethasone \[[@b8-medscimonitbasicres-24-47],[@b37-medscimonitbasicres-24-47],[@b54-medscimonitbasicres-24-47]\]. The (GIOP) rat study groups were as follows:

1.  **Group 1:** The non-treated (control) group (n=6).

2.  **Group 2:** The dexamethasone-treated group, treated subcutaneously with 120 μg/kg dexamethasone, administered for 30 days as a single dose per day (n=6).

3.  **Group 3:** The zaprinast + dexamethasone group, treated with 10 mg/kg oral zaprinast plus 120 μg/kg subcutaneous dexamethasone, administered for 30 days as a single dose per day (n=6).

4.  **Group 4:** The avanafil + dexamethasone group 10 mg/kg oral avanafil plus 120 μg/kg subcutaneous dexamethasone, administered for 30 days as a single dose per day (n=6).

Measurement of bone mineral density (BMD) using dual-energy X-ray absorptiometry (DEXA)
---------------------------------------------------------------------------------------

Bone mineral density (BMD) was measured under anesthesia by a dual-energy X-ray absorptiometry (DEXA) device (Hologic, QDR-Discovery C Hologic, Inc., Waltham, MA, USA). The device used was suitable for the rats, and was used before and after the administration of dexamethasone, and treatment in all of the groups. The measurement of BMD was performed by whole-body scanning under anesthesia before and after the dexamethasone and PDE-5 inhibitor administration in the live experimental animals. The BMD results obtained were expressed as gm/cm^2^.

Rat urine sample analysis
-------------------------

Before and after the administration of dexamethasone and PDE-5 inhibitor therapy, 24-hour urine samples were collected from all the rats, by was collection using metabolic animal cages. Urine samples were stored at −80°C until further analysis. The values of the bone resorption markers, pyridinoline (PD) and deoxypyridinoline (DPD) were measured in the urine samples.

Blood and bone tissue samples
-----------------------------

At the end of the 30-day treatment period, the rats were anesthetized and euthanized. Bone tissue and intracardiac blood samples were taken. Some of the whole blood was centrifuged at 2500×g for 15 min and the plasma samples obtained were divided and stored at −80°C until required for further study. The other part of the whole blood sample was reserved for the measurement of 8-hydroxy-2′-deoxyguanosine (8-OHdG) and deoxyguanosine (dG). The right femoral bone tissues from the rats were preserved in 10% formalin for histopathological and immunohistochemical examination by light microscopy.

Biochemical analysis using the enzyme-linked immunosorbent assay (ELISA)
------------------------------------------------------------------------

Endothelial nitric oxide synthase (eNOS), nitric oxide (NO), phosphodiesterase-5 (PDE-5), cyclic guanosine monophosphate (cGMP), and protein kinase G (PKG) associated with the nitric oxide (NO) signaling pathway, C-terminal telopeptide of type I collagen (CTX-1), and procollagen type I carboxy-terminal extension peptide (PICP) indicating bone activity in the plasma samples, and pyridinoline (PD) and deoxypyridinoline (DPD) which are bone destruction markers in the urine, as well as cortisol levels, were measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit, according to the manufacturer's instructions (Hangzhou Eastbiopharm Co. Ltd.).

Measurement of plasma malondialdehyde (MDA) using high-pressure liquid chromatography (HPLC)
--------------------------------------------------------------------------------------------

Plasma MDA levels were measured according to the method described by Khoschsorur et al. \[[@b38-medscimonitbasicres-24-47]\]. In this method, 750 μL and 0.44 M H~3~PO~4~, 250 μL and 0.25 mM thiobarbituric acid (TBA), and 450 μL distilled water were added to a 50 μL plasma sample. The tubes were tightly sealed and kept in a boiling water bath for 60 min and then cooled with tap water. Then, alkene methylation was performed with 50 mL methanol and 4.5 mL NaOH, added in a 1: 1 (v/v) ratio. The mixture was then centrifuged at 2,500×g for 3 min., and 200 μL of the supernatant remaining in the upper phase was removed and placed in a vial, where it was then transferred to for high-pressure liquid chromatography (HPLC) using an RP18 column, of 150×4.6 mm length and 5 μm particle size, as the measurement column. For the mobile phase, 400 mL of 50 mM phosphate buffer (pH: 6.8) and 600 mL of pure methanol were prepared by mixing. The flow rate of the device was set to 0.8 mL/min and the injection volume to 20 μL. The MDA and thiobarbituric acid (TBA) complex were measured and compared with standard samples prepared at different concentrations with 1,1,3,3 tetra-ethoxypropane, in the fluorescence detector at 527 nm excitation and 551 nm emission wavelengths. The results obtained were expressed in μM.

Measurement of plasma co-enzyme ubiquinone-10 (CoQ10) using HPLC
----------------------------------------------------------------

The measurement of plasma CoQ10 was performed according to the method of Litarru et al. \[[@b39-medscimonitbasicres-24-47],[@b40-medscimonitbasicres-24-47]\]. The preparation of oxidized CoQ10 included 50 μL of benzoquinone (2 mg/mL), which was added to the 200 μL plasma sample and vortexed for 10 sec. After incubation at room temperature for 10 min, 1 mL of propanol was added. The mixture was vortexed for 10 sec, and then centrifuged at 4000×g for 6 min. 200 μL of the supernatant from the upper phase was placed in a vial and loaded into the HPLC apparatus. A mixture of 650 mL of ethanol and 350 mL of methanol was used for the mobile phase. A C18 column with a 5 μm particle size and a length of 25×4.6 mm was used. The flow rate of the device was set to 0.8 mL/min and the injection volume to 20 μL. The measurement was performed against the standards prepared at different concentrations, and using an ultraviolet (UV) detector at 275 nm.

Measurement of total CoQ10 and the ubiquinone-10 (CoQ10), ubiquinol CoQ10 (CoQ10H) ratio
----------------------------------------------------------------------------------------

The method used 50 μL of benzoquinone (2 mg/mL), which was added to the 200 μL plasma samples and vortexed for 10 sec. One milliliter of lithium perchlorate was then added to the mixture. One mililiter of propanol was added after incubation at room temperature for 10 min. The mixture was again vortexed for 10 sec and centrifuged at 4,000×g for 6 minutes and 200 μL of the supernatant was placed in a vial and loaded into the HPLC device. A mixture of pure ethanol, pure methanol, and lithium perchlorate (50 mM) in a volume ratio of 70: 20: 10 was used for the mobile phase. A C18 column, 25×4.6 mm in length and with a 5 μm particle size was used as the column. The flow rate of the device was set to 0.8 mL/min and the injection volume was set to 20 μL. The measurements were performed against the standards prepared at different concentrations in the UV detector at 275 nm. The results were expressed as a ubiquinone-10 (CoQ10), ubiquinol CoQ10 (CoQ10H) ratio with the help of the CoQ10/Total CoQ10 -- oxidized CoQ10 equation.

Measurement of 8-hydroxy-2′-deoxyguanosine (8-OHdG) and deoxyguanosine (dG) using HPLC with electrochemical detection (ECD)
---------------------------------------------------------------------------------------------------------------------------

Leukocyte DNA was isolated from whole blood samples using a DNA isolation kit (Invitrogen, CA, USA) in accordance with the manufacturer's guidelines. According to the method of Kaur et al. \[[@b41-medscimonitbasicres-24-47]\], a 150 μL DNA sample was added to the same volume of pure formic acid and incubated at 150°C for 30 min. 100 μL of acetonitrile was then added, and 8-OHdG at 600 mV using HPLC with electrochemical detection (ECD), and dG at 275 nm in the UV detector were measured against different standards using the HPLC. The mobile phase was prepared by mixing 30 mL of acetonitrile in 970 mL of phosphate buffer (pH: 5.5 and 50 mM). A C18 column, with a length of 15×4.6 mm and 5 μm particle size was used. The flow rate of the device was set to 0.8 mL/min and the injection volume to 20 μL. The results were expressed as the number of 8-OHdG/10^6^dG.

Histopathological and immunohistochemical evaluation of bone tissue from the right femur of the rats in the GIOP model
----------------------------------------------------------------------------------------------------------------------

At the end of the study, the rats were euthanized and necropsy was performed to remove the right femoral bone from all rats. Bone specimens were fixed in a 10% formalin solution for 48 hours. The bone tissues were decalcified by incubated in osteosoft solution (MERC, HC313331, Germany) for between 96−120 hours. The tissues were then washed in tap water for 24 hours. After routine tissue processing and sectioning for histopathological evaluation, the right femoral bone samples were embedded in paraffin wax blocks and 4 μm thick sections were cut from each block and onto glass slides. The sections were stained with hematoxylin and eosin (H&E) for histopathologic examination and to examine the epiphyseal bone width of the right femoral head and trabecular bone thickness by light microscopy (Leica DM1000).

Immunohistochemical staining was performed according to the method of Shi et al. \[[@b42-medscimonitbasicres-24-47]\]. After deparaffinization and dehydration, the tissue sections were microwaved in an antigen-retrieval solution (citrate buffer, pH 6.1), four times for 5 min. After the preparations were cooled and washed, they were dried and the boundaries of the sections were drawn with a glass marker pen. For the inhibition of endogenous peroxidase activity, the sections were washed with a phosphate buffer solution (PBS, pH 7.2) for 5 minutes and incubated in a 3% H~2~O~2~ solution for 10 minutes. After the sections were washed in PBS, they were incubated with a protein solution for 5 minutes to prevent nonspecific antibody staining.

Then, the sections were incubated with the primary antibody to the endothelial cell marker, CD31 (PA5-16301) (Thermo Scientific, USA) at room temperature for 1 hour. The sections were washed with PBS for 10 min, and were then incubated with the specific anti-polyvalent horse-radish peroxidase (HRP)-conjugated immunohistochemistry (IHC) detection kit (CAT: TP-060-HL) (Thermo Scientific, USA) at room temperature for between 10−30 min, as recommended by the manufacturer. After repeated washing, 3-amino-9-ethyl-carbazole (AEC) was used as the chromogen and incubated with the sections for between 5−10 min. The sections were incubated with Mayer's hematoxylin for between 1−2 minutes and washed in tap water. The tissue sections were then covered with glass coverslips using water-based mountant and examined for angiogenesis in bone marrow of the right femur of each rat, by light microscopy (Leica DM1000).

Statistical analysis
--------------------

Numerical data were expressed as the mean ± standard deviation (SD). Repeated analysis of variance (ANOVA) was performed to compare the means of the measurements in each of the four of groups of rats before and after ovariectomy and after treatment with the PDE-5 inhibitors, avanafil and zaprinast. The Duncan multiple comparison test was used to identify the different groups. The Pearson correlation coefficients were calculated separately for each group by determining the relationship between the variables after the administration of dexamethasone and the PDE-5 inhibitor. The level of statistical significance in the calculations was taken as p\<0.05. The SPSS statistical package program, version 15, was used for the calculations.

Results
=======

Body weight of the animals in the rat model of glucocorticoid-induced osteoporosis (GIOP)
-----------------------------------------------------------------------------------------

The weight of the rats before the administration of dexamethasone and 'the PDE-5 inhibitors, avanafil and zaprinast, were measured. Before the start of the study, the mean weights of the rats in the control, dexamethasone, dexamethasone + zaprinast, and dexamethasone + avanafil groups were 329±16 g, 325±17 g, 332±19 g, and 356±14 g, respectively; there was no significant differences between the groups. At the end of the study, the mean weights of the control, dexamethasone, dexamethasone + zaprinast, and dexamethasone + avanafil were 341±16 g, 344±13 g, 357±17 g, and 374±19 g, respectively; there were no significant differences between the groups. Also, there was only a partial change in the weights of the rats in the same groups before and after the application dexamethasone and PDE-5 inhibitors during the 30-day study.

Dexamethasone and the nitric oxide (NO) signaling pathway
---------------------------------------------------------

Some important biochemical markers of the nitric oxide (NO) signaling pathway, bone formation and degradation, and oxidative stress parameters are shown in [Table 1](#t1-medscimonitbasicres-24-47){ref-type="table"}. After the administration of dexamethasone and PDE-5 inhibitor, the levels of endothelial nitric oxide synthase (eNOS) and NO levels in all the rat groups treated with dexamethasone were significantly increased compared with the control group (p\<0.05). However, there was no significant difference between the eNOS levels in the group treated with dexamethasone. Also, NO levels were significantly lower in the dexamethasone + zaprinast and dexamethasone + avanafil groups compared with the dexamethasone-treated group (p\<0.05). While there was no significant difference between PDE-5 values in the (non treated) control, and the dexamethasone-treated groups, these values in the dexamethasone + zaprinast and dexamethasone + avanafil groups were significantly lower when compared with the control and dexamethasone groups (p\<0.05).

Levels of cyclic guanosine monophosphate (cGMP) were significantly increased in all of the rat groups treated with dexamethasone (p\<0.05). This increase was greater in the dexamethasone + zaprinast group, and particularly high in the dexamethasone + avanafil group (p\<0.05). There was no significant difference in the protein kinase G (PKG) values of the (untreated) control, dexamethasone, and dexamethasone + zaprinast groups. However, the PKG value was significantly increased in the dexamethasone + avanafil group compared with the other groups (p\<0.05).

Procollagen type I carboxy-terminal extension peptide (PICP) values were significantly increased in the control group compared with all the other groups given dexamethasone (p\<0.05). However, PICP values were significantly lower in the dexamethasone + zaprinast and dexamethasone + avanafil groups compared with the dexamethasone group (p\<0.05). While there was no significant difference between the C-terminal telopeptide of type I collagen (CTX-1) values of the control and dexamethasone groups, these values were significantly increased in the dexamethasone + zaprinast and dexamethasone + avanafil groups compared with the control and the dexamethasone-treated groups (p\<0.05).

Cortisol and the oxidative stress parameters, malondialdehyde (MDA), ubiquinone-10 (CoQ10), ubiquinol CoQ10 (CoQ10H), and 8-hydroxy-2′-deoxyguanosine (8-OHdG)
--------------------------------------------------------------------------------------------------------------------------------------------------------------

The plasma cortisol levels of all of the groups treated with dexamethasone were reduced by about 50% when compared with the control group (p\<0.05) ([Table 1](#t1-medscimonitbasicres-24-47){ref-type="table"}). Also, malondialdehyde (MDA) and ubiquinone-10 (CoQ10), ubiquinol CoQ10 (CoQ10H) levels were significantly increased in all of the groups given dexamethasone (p\<0.05) ([Table 1](#t1-medscimonitbasicres-24-47){ref-type="table"}). However, the increase in the CoQ10 and CoQ10H ratio was not significantly increased in the dexamethasone + zaprinast and the dexamethasone + avanafil groups and were similar to the control group. The dexamethasone + zaprinast and dexamethasone + avanafil groups also had reduced MDA levels when compared with the dexamethasone-treated group. The rates of 8-hydroxy-2′-deoxyguanosine (8-OHdG), measured to determine oxidative DNA damage, were significantly increased in the dexamethasone group when compared with the control group, while levels were significantly decreased in the dexamethasone + zaprinast group and the dexamethasone + avanafil group (p\<0.05).

Histopathological and immunohistochemical evaluation of bone tissue from the right femur in the rat model of glucocorticoid-induced osteoporosis (GIOP)
-------------------------------------------------------------------------------------------------------------------------------------------------------

Immunohistochemical examination of the experimental animals showed that angiogenesis (CD31-positive cells) in the right femoral bone marrow was significantly increased in all groups given dexamethasone when compared with the control group. However, this increase in bone marrow angiogenesis was increased, in parallel to the activation of the NO signaling pathway, in the dexamethasone + zaprinast and dexamethasone + avanafil groups ([Figure 1](#f1-medscimonitbasicres-24-47){ref-type="fig"}; [Table 2](#t2-medscimonitbasicres-24-47){ref-type="table"}). The dexamethasone + zaprinast group, and particularly the dexamethasone + avanafil group, had a significantly increased right femur trabecular bone thickness and epiphyseal bone width when compared with the dexamethasone-treated group on histopathologic examination in the right femoral tissue, and these were similar to the control group ([Figures 2](#f2-medscimonitbasicres-24-47){ref-type="fig"}, [3](#f3-medscimonitbasicres-24-47){ref-type="fig"}; [Table 2](#t2-medscimonitbasicres-24-47){ref-type="table"}).

Whole-body bone mineral density (WB-BMD)
----------------------------------------

The whole-body bone mineral density (WB-BMD) values measured radiologically were very close to each other in all of the rat groups before the administration of dexamethasone and the PDE-5 inhibitors, as follows: control or untreated group, 0.203±0.008 g/cm^2^; dexamethasone-treated group, 0.204±0.005 g/cm^2^; dexamethasone + zaprinast group, 0.205±0.004 g/cm^2^; and the dexamethasone + avanafil group, 0.206±0.005 g/cm^2^.

The bone mineral density (BMD) values were partially elevated due increasing age of the animals during the 30-day period of the study in all groups, after the application of dexamethasone and PDE-5 inhibitor, as follows: control or untreated group, 0.246±0.008 g/cm^2^; the dexamethasone-treated group, 0.215±0.005 g/cm^2^; the dexamethasone + zaprinast group, 0.220±0.003 g/cm^2^; and the dexamethasone + avanafil group, 0.232±0.005 g/cm^2^. Also, the dexamethasone + avanafil group had the highest BMD value in all groups given dexamethasone treatment, and these values were similar to the control (untreated) group values ([Figure 4A](#f4-medscimonitbasicres-24-47){ref-type="fig"}).

Mean pyridinoline (PD) and deoxypyridinoline (DPD) values
---------------------------------------------------------

The mean pyridinoline (PD) values, measured in the rat urine, as markers of bone resorption, were found to vary between 5.872± 0.157 and 7.061± 0.784 nmol/mL before the application of dexamethasone and PDE-5 inhibitor, and changed to between 4.601± 1.179 and 7.701±1.313 nmol/mL after the administration of dexamethasone and PDE-5 inhibitor. Also, the mean PD values of the dexamethasone + avanafil group were lowest compared with the other groups after the application of dexamethasone and PDE-5 inhibitor ([Figure 4B](#f4-medscimonitbasicres-24-47){ref-type="fig"}).

The findings for the deoxypyridinoline (DPD) levels were similar. The mean DPD values changed between of 35.858±4.921 and 36.684±3.321 nmol/mL before the application of dexamethasone and PDE-5 inhibitor, and there was no significant difference between the groups. However, the DPD values of all of the groups after the application of dexamethasone and PDE-5 inhibitor changed to between of 30.938±7.966 and 46.452±8.623 nmol/mL and these values were lower in the dexamethasone + zaprinast and dexamethasone + avanafil groups compared with the dexamethasone-treated group ([Figure 4C](#f4-medscimonitbasicres-24-47){ref-type="fig"}).

Discussion
==========

The long-term use of glucocorticoids, such as dexamethasone, as anti-inflammatory and immunosuppressive drugs, can increase the risk of developing osteoporosis and its complications \[[@b43-medscimonitbasicres-24-47]\]. Glucocorticoids suppress bone formation by reducing the lifespan of osteoblasts and inhibiting the formation of new osteoblast cells \[[@b44-medscimonitbasicres-24-47]\].

Kann et al. found that the administration of dexamethasone, a synthetic glucocorticoid, to healthy subjects and patients with primary estrogen-related osteoporosis, had serum cortisol levels that were suppressed by about 15.4% \[[@b45-medscimonitbasicres-24-47]\]. In the present study, plasma cortisol levels in the all of the groups given dexamethasone were about 53.29% lower when compared with the control group. This result may be due to the physiological response of the rat model of glucocorticoid-induced osteoporosis (GIOP) to the high concentrations of dexamethasone.

There are several potential factors that may that prevent the development of osteoporosis. One of these possible factors is nitric oxide (NO), which regulates bone regeneration *in vivo* \[[@b46-medscimonitbasicres-24-47],[@b47-medscimonitbasicres-24-47]\]. Previously published studies have demonstrated that the endothelial nitric oxide synthase (eNOS) and NO signaling pathway activation can reduce bone loss and improve osteoblastic activity and bone turnover \[[@b48-medscimonitbasicres-24-47]--[@b53-medscimonitbasicres-24-47]\]. It has previously been reported that phosphodiesterase-5 (PDE-5) inhibitors may positively contribute to increasing bone mineral density (BMD) and angiogenesis by reducing the hydrolysis of cyclic guanosine monophosphate (cGMP) in the NO signaling pathway \[[@b8-medscimonitbasicres-24-47],[@b26-medscimonitbasicres-24-47],[@b54-medscimonitbasicres-24-47]\]. There have some previous studies on the effect of the PDE-5 inhibitors on osteoporosis \[[@b8-medscimonitbasicres-24-47],[@b25-medscimonitbasicres-24-47],[@b54-medscimonitbasicres-24-47]\] and there are no studies on the therapeutic effects of the PDE-5 inhibitors, zaprinast or avanafil, in humans or animals with osteoporosis. In these previously published studies, PDE-5 inhibitors, including sildenafil, vardenafil, tadalafil and udenafil increased angiogenesis in the bone marrow by activating the NO/cGMP/protein kinase G signaling pathway components in rats with osteoporosis, as well as increasing BMD, epiphyseal bone width, and bone healing \[[@b8-medscimonitbasicres-24-47],[@b25-medscimonitbasicres-24-47],[@b54-medscimonitbasicres-24-47]\]. In the present study, the PDE-5 inhibitor, zaprinast, and especially avanafil, increased BMD and growth plate width as well as angiogenesis in the bone marrow of rats with GIOP. This data supports the view that increasing angiogenesis in bone marrow may contribute positively to increasing bone tissue and bone turnover.

C-terminal telopeptide of type I collagen (CTX-1) and procollagen type I carboxy-terminal extension peptide (PICP) are the most important biomarkers in bone formation and turnover indicating osteoblastic activity, whereas pyridinoline (PD) and deoxypyridinoline (DPD) levels in the urine are markers of bone destruction \[[@b54-medscimonitbasicres-24-47],[@b55-medscimonitbasicres-24-47]\]. In a previously published study from our group, we found that vardenafil, tadalafil, and udenafil treatment significantly increased the levels of procollagen type I carboxy-terminal extension peptide (PICP) and reduced PD and DPD levels in rats with ovariectomy-induced osteoporosis \[[@b55-medscimonitbasicres-24-47]\]. In the present study, while the PICP values were elevated in the dexamethasone-treated group, they were reduced in the dexamethasone + zaprinast and dexamethasone + avanafil groups. However, CTX-1 values were significantly increased in the dexamethasone + zaprinast and dexamethasone + avanafil groups when compared with the control and the dexamethasone-treated groups. The high CTX-1 as well as low DP and DPD values in the dexamethasone + zaprinast group and especially in the dexamethasone + avanafil group, when compared with the dexamethasone-treated group, indicated that osteoblastic activity was increased and bone destruction was decreased by treatment with the PDE-5 inhibitors, zaprinast and avanafil, in the GIOP rat model.

Dual-energy X-ray absorptiometry (DEXA) measurements have previously been reported to show that a low BMD is one of the most important findings indicating a high risk of osteoporotic vertebral fractures, and is used in the diagnosis and follow-up of osteoporosis \[[@b56-medscimonitbasicres-24-47],[@b57-medscimonitbasicres-24-47]\]. There have been several studies that have reported that BMD was reduced in control or sham groups consisting of ovariectomized female rats receiving glucocorticoids \[[@b58-medscimonitbasicres-24-47]--[@b60-medscimonitbasicres-24-47]\]. In our previous study, we also showed that BMD was significantly reduced in ovariectomized (OVX) female rats, but was increased and similar to the control levels in the OVX + PDE-5 inhibitor-treated groups \[[@b55-medscimonitbasicres-24-47]\]. In the present study, the low BMD in the dexamethasone-treated groups indicated that osteoporosis developed in the dexamethasone-treated rats; the fact that BMD in the dexamethasone +zaprinast group, and especially the dexamethasone + avanafil group was greater than that of the dexamethasone-treated group and similar to the control group, indicating that PDE-5 inhibitors may have a positive effect on increasing BMD.

It has been previously demonstrated that, following the administration of dexamethasone, antioxidant depletion, increased levels of reactive oxygen species (ROS), and lipid peroxidation may play an important role in the pathogenesis of osteoporosis in the GIOP rat model \[[@b61-medscimonitbasicres-24-47]\]. Several previous studies have shown that oxidative damage is increased in response to exposure to high-dose dexamethasone \[[@b62-medscimonitbasicres-24-47]--[@b68-medscimonitbasicres-24-47]\]. From review of the published literature, there have been no previously published studies on the lipid peroxidation or oxidative stress parameters of the PDE-5 inhibitors, zaprinast and avanafil in GIOP.

In the present study, it was shown that malondialdehyde (MDA) levels from lipid peroxidation products \[[@b69-medscimonitbasicres-24-47]--[@b71-medscimonitbasicres-24-47]\], were significantly increased in the rat groups treated with dexamethasone. MDA levels were significantly increased in the dexamethasone-treated group when compared with groups treated with the PDE-5 inhibitors, zaprinast or avanafil together with dexamethasone. Ubiquinone-10 (CoQ10), ubiquinol CoQ10 (CoQ10H), and 8-hydroxy-2′-deoxyguanosine (8-OHdG) are now known to be some of the most important markers of mitochondrial damage \[[@b72-medscimonitbasicres-24-47]\] and oxidative DNA damage, respectively \[[@b73-medscimonitbasicres-24-47],[@b74-medscimonitbasicres-24-47]\]. In the present study, CoQ10 and 8-OHdG were increased in all of the groups of rats treated with dexamethasone. However, the levels of the ratios of CoQ10 and CoQ10H, and of 8-OHdG and dG were significantly lower in the zaprinast and avanafil + dexamethasone treated groups compared with the dexamethasone-treated groups. These results indicated that oxidative stress was significantly increased with the use of dexamethasone, but that the PDE-5 inhibitors, zaprinast and especially avanafil, significantly inhibited oxidative stress when given with dexamethasone in the GIOP rat model.

Conclusions
===========

The findings this study, in a rat model of glucocorticoid-induced osteoporosis (GIOP), showed that dexamethasone administration significantly increased bone atrophy, reduced bone mineral density (BMD), and oxidative stress in the rat femur. However, treatment with the phosphodiesterase-5 (PDE-5) inhibitors, zaprinast and avanafil, significantly increased angiogenesis in bone tissue via the activation of components of the nitric oxide (NO), cyclic guanosine monophosphate (cGMP), and protein kinase G (PKG) (NO/cGMP/PKG) signaling-pathway and significantly decreased dexamethasone-induced loss in BMD, bone atrophy, and oxidative stress. Further molecular studies and controlled clinical studies are required to determine how PDE-5 inhibitors exert the effects found in this animal model study of osteoporosis. Specifically, the effects of zaprinast and avanafil on the effects of the parathyroid hormone analog, teriparatide, and on bone morphogenetic protein (BMP)2 and BMP4 that are known to have a positive effect on BMD, are recommended in patients with osteoporosis.
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![Photomicrographs of new vessel formation (angiogenesis) in the bone marrow of the right femur in the rat model of glucocorticoid-induced osteoporosis (GIOP) treated with dexamethasone or the phosphodiesterase-5 (PDE-5) inhibitors, avanafil and zaprinast. (**A**) The control (untreated) group. (**B**) The dexamethasone-treated group. (**C**) The dexamethasone + zaprinast-treated group. (**D**) The dexamethasone + avanafil-treated group. The histological tissue sections viewed by light show new vessel formation. Scale bar: 20 μm. Hematoxylin and eosin (H&E).](medscimonitbasicres-24-47-g001){#f1-medscimonitbasicres-24-47}

![Images showing the bone mineral density (BMD) of the right femoral head in rats with glucocorticoid-induced osteoporosis (GIOP). (**A**) The control (untreated) group. (**B**) The dexamethasone-treated group. (**C**) The dexamethasone + zaprinast-treated group. (**D**) The dexamethasone + avanafil-treated group. The channels indicate mineral deposits. Scale bar: 100 μm.](medscimonitbasicres-24-47-g002){#f2-medscimonitbasicres-24-47}

![Images showing the right femur epiphyseal bone width in rats with glucocorticoid-induced osteoporosis (GIOP). (**A**) The control (untreated) group. (**B**) The dexamethasone-treated group. (**C**) The dexamethasone + zaprinast-treated group. (**D**) The dexamethasone + avanafil-treated group. The area or distance between of the two arrows indicates the epiphyseal area (bone growth plate). Scale bar: 50 μm.](medscimonitbasicres-24-47-g003){#f3-medscimonitbasicres-24-47}

![Comparison of bone mineral density, pyridinoline (PD), and deoxypyridinoline (DPD) values before and after treatment with dexamethasone and the phosphodiesterase-5 (PDE-5) inhibitors, avanafil and zaprinast. (**A**) The radiologically measured values of bone mineral density (BMD) (g/cm^2^). (**B**) Urine pyridinoline (PD) values (nmol/mL). (**C**) Urine deoxypyridinoline (DPD) values (nmol/mL). \* p\<0.05: when compared with the control group after the administration of dexamethasone and the phosphodiesterase-5 (PDE-5) inhibitor. ^\#^ p\<0.05: when compared with the other groups after the administration of dexamethasone and the phosphodiesterase-5 (PDE-5) inhibitor. ^@^ p\<0.05: when compared with the administration of dexamethasone and the phosphodiesterase-5 (PDE-5) inhibitor in the same group. ^a^ p\<0.05: when compared with the other groups before the administration of dexamethasone and the PDE-5 inhibitor in the same group.](medscimonitbasicres-24-47-g004){#f4-medscimonitbasicres-24-47}

###### 

The comparison of NO signaling pathway, some bone formation and degradation markers, cortisol and some oxidative stress parameter values in rats with glucocorticoid-induced osteoporosis.

                    Control         DEX                                                                       DEX + Zaprinast                                                           DEX + Avanafil
  ----------------- --------------- ------------------------------------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  eNOS (ng/mL)      51.804±0.333    56.038±0.660[\*](#tfn1-medscimonitbasicres-24-47){ref-type="table-fn"}    56.460±0.500[\*](#tfn1-medscimonitbasicres-24-47){ref-type="table-fn"}    56.279±0.421[\*](#tfn1-medscimonitbasicres-24-47){ref-type="table-fn"}
  NO (μmol/L)       186.554±2.290   202.109±3.394[\*](#tfn1-medscimonitbasicres-24-47){ref-type="table-fn"}   196.561±3.966[\#](#tfn2-medscimonitbasicres-24-47){ref-type="table-fn"}   199.212±3.522[\#](#tfn2-medscimonitbasicres-24-47){ref-type="table-fn"}
  PDE-5 (ng/mL)     5.247±0.046     5.038±0.377                                                               4.656±0.605[\#](#tfn2-medscimonitbasicres-24-47){ref-type="table-fn"}     3.877±0.554[\#](#tfn2-medscimonitbasicres-24-47){ref-type="table-fn"},[@](#tfn3-medscimonitbasicres-24-47){ref-type="table-fn"}
  cGMP (pmol/L)     37.901±0.440    40.752±0.645[\*](#tfn1-medscimonitbasicres-24-47){ref-type="table-fn"}    42.515±0.348[\#](#tfn2-medscimonitbasicres-24-47){ref-type="table-fn"}    45.481±0.511[\#](#tfn2-medscimonitbasicres-24-47){ref-type="table-fn"},[@](#tfn3-medscimonitbasicres-24-47){ref-type="table-fn"}
  PKG (ng/mL)       11.821±0.164    11.744±0.161                                                              11.914±0.238                                                              14.710±0.332[@](#tfn3-medscimonitbasicres-24-47){ref-type="table-fn"}
  PICP (ng/mL)      68.105±0.781    72.595±0.434[\*](#tfn1-medscimonitbasicres-24-47){ref-type="table-fn"}    63.625±0.317[\#](#tfn2-medscimonitbasicres-24-47){ref-type="table-fn"}    62.897±0.724[\#](#tfn2-medscimonitbasicres-24-47){ref-type="table-fn"}
  CTCP (ng/mL)      5.668±0.026     5.702±0.061                                                               5.813±0.058[\#](#tfn2-medscimonitbasicres-24-47){ref-type="table-fn"}     6.389±0.023[@](#tfn3-medscimonitbasicres-24-47){ref-type="table-fn"}
  Cortisol (ng/L)   92.817±2.872    42.742±2.685[\*](#tfn1-medscimonitbasicres-24-47){ref-type="table-fn"}    41.282±1.731[\*](#tfn1-medscimonitbasicres-24-47){ref-type="table-fn"}    46.037±3.712[\*](#tfn1-medscimonitbasicres-24-47){ref-type="table-fn"}
  MDA (μM)          1.702±0.047     2.150±0.124[\*](#tfn1-medscimonitbasicres-24-47){ref-type="table-fn"}     2.006±0.101[\#](#tfn2-medscimonitbasicres-24-47){ref-type="table-fn"}     1.980±0.104[\#](#tfn2-medscimonitbasicres-24-47){ref-type="table-fn"}
  CoQ10/CoQ10H      0.301±0.032     0.402±0.026[\*](#tfn1-medscimonitbasicres-24-47){ref-type="table-fn"}     0.331±0.044                                                               0.332±0.029
  8-OHdG/10^6^dG    0.666±0.097     0.831±0.073[\*](#tfn1-medscimonitbasicres-24-47){ref-type="table-fn"}     0.500±0.094[\#](#tfn2-medscimonitbasicres-24-47){ref-type="table-fn"}     0.486±0.095[\#](#tfn2-medscimonitbasicres-24-47){ref-type="table-fn"}

When compared to the control group in each line (p\<0.05).

When compared to the control and DEX groups in each line (p\<0.05).

When compared to the other groups in each line (p\<0.05).

eNOS -- endothelial nitric oxide synthase; NO -- nitric oxide; PDE-5 -- phosphodiesterase-5; cGMP -- cylic guanosine mono phosphate; PKG -- protein kinase G; PICP -- procollagen peptide; CTCP -- cterminal collagen peptide; MDA -- malondialdehyde; CoQ10 -- ubiquinone 10; 8-OHdG -- 8-hydroxy-2-deoxyguanosine; dG -- deoxyguanosine.

###### 

The comparison of right femur trabecular bone density, new vascular formation and epiphyseal bone width of all groups in rats with glucocorticoid-induced osteoporosis.

  Groups          Right femur visual trabecular density (mm^2^)   Right femur visual new vessel density (mm^2^)   Right femur epiphyseal width (px)
  --------------- ----------------------------------------------- ----------------------------------------------- ---------------------------------------------------------------------------
  Control         \+ + + +                                        ++                                              1565.357±33.640[\*](#tfn5-medscimonitbasicres-24-47){ref-type="table-fn"}
  DEX             \+                                              \+ +                                            983.433±34.633[\*](#tfn5-medscimonitbasicres-24-47){ref-type="table-fn"}
  DEX+Zaprinast   \+ + +                                          \+ + +                                          1124.123±32.196[\*](#tfn5-medscimonitbasicres-24-47){ref-type="table-fn"}
  DEX+Avanafil    \+ + + +                                        \+ + + +                                        1217.607±33.102[\*](#tfn5-medscimonitbasicres-24-47){ref-type="table-fn"}

p\<0.001 -- when compared to the other groups;

\+ -- It is a semicantitavie evaluation as visual.

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection
